Triangle Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Durham NC United States (1995)
Status: Acquired by Gilead Sciences (2003)

Organization Overview

First Clinical Trial
1999
NCT00196599
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2002

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

HIV Infections (Phase 3)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 14